Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15638869 | 0.84 | TGFBR1 (0.65) | KDM4EALDH1A1SCN5ALMNADYRK1A | |
| SCHEMBL20190372 | 0.84 | SCN5A (0.68) | KDM4EALDH1A1SCN5ALMNADYRK1A | |
| SCHEMBL1346620 | 0.79 | TP53 (0.52) | KDM4EALDH1A1CTSSKMOIDO1 | |
| SCHEMBL11478689 | 0.78 | KDM4E (1.00) | KDM4EALDH1A1LMNAKDM1ACTSS | |
| SCHEMBL11472275 | 0.77 | KCNN3 (0.50) | KDM4EALDH1A1DYRK1AKDM1ACTSS | |
| SCHEMBL11467424 | 0.77 | CTSS (0.49) | KDM4EALDH1A1DYRK1AKDM1ACTSS | |
| SCHEMBL3162678 | 0.76 | DYRK1A (0.65) | KDM4EALDH1A1SCN5ADYRK1ATGFBR1 | |
| SCHEMBL1348527 | 0.75 | PIK3CG (0.57) | KDM4EALDH1A1DYRK1ACTSSKMO | |
| SCHEMBL3346835 | 0.73 | GRM5 (0.50) | KDM4EALDH1A1SCN5ATGFBR1 | |
| SCHEMBL3175273 | 0.73 | KDM4E (0.55) | KDM4EALDH1A1LMNATGFBR1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | claimed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | claimed |
| EP-1713808-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT, INC. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005070931-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC. (US) | 2005-08-04 | — | — | WO | claimed |
| US-4178449-A | Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1979-12-11 | — | — | US | claimed |
| US-8063048-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100210642-A1 | ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES | GATTI MCARTHUR SILVIA | 2010-08-19 | — | — | US | disclosed |
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080300250-A1 | ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES | GATTI MCARTHUR SILVIA | 2008-12-04 | — | — | US | disclosed |
| EP-1863818-A1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1713808-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT, INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006099972-A1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| WO-2005070931-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-4236005-A | ANTIANXIETY | AMERICAN CYANAMID COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
| US-4178449-A | Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1979-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210642-A1 | ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES | NAT1, TPMT, ACAT1 | KDM4E 1335/4885ALDH1A1 90/4885SCN5A 1515/4885 |
| US-20080300250-A1 | ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES | NAT1, TPMT, ACAT1 | KDM4E 1335/4885ALDH1A1 90/4885SCN5A 1515/4885 |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | AZI2, CDK2, TPMT | KDM4E 3705/4885ALDH1A1 1128/4885SCN5A 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.